Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly

Neurology

Volumn 87, Issue 9, 2016, Pages 920-926

  Chhatwal, Jasmeer P ^a,b   Schultz, Aaron P ^a,b   Marshall, Gad A ^a,b,c   Boot, Brendon ^a,b,c,d   Gomez Isla, Teresa ^a,b   Dumurgier, Julien ^b,e   La Point, Molly ^b   Scherzer, Clemens ^a,c,f   Roe, Allyson D ^b   Hyman, Bradley T ^a,b   Sperling, Reisa A ^a,b,c   Johnson, Keith A ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BIOGEN   (United States)

^e HÔPITAL LARIBOISIÈRE   (France)

^f The Harvard Center for Neurodegeneration & Repair   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORTAUCIPIR F 18; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CARBOLINE DERIVATIVE;

AGED; ARTICLE; DRUG UPTAKE; ENTORHINAL CORTEX; FEMALE; HUMAN; INFERIOR PARIETAL CORTEX; INFERIOR TEMPORAL CORTEX; MALE; MEDIAL FRONTAL CORTEX; MIDDLE TEMPORAL GYRUS; NORMAL HUMAN; PARAHIPPOCAMPAL GYRUS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SUPERIOR TEMPORAL GYRUS; BRAIN; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; GENETICS; GERIATRIC ASSESSMENT; MENTAL HEALTH; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORYLATION; TEMPORAL LOBE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BRAIN; CARBOLINES; CROSS-SECTIONAL STUDIES; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TEMPORAL LOBE;

EID: 84984815332     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003050     Document Type: Article

References (24)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319
2. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging, and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-1791
3. Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of b-amyloid, and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014; 71: 1379-1385
4. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765-775
5. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013; 9: 666-676
6. Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease, and non-Alzheimer's disease tauopathies. Alzheimers Res Ther 2014; 6: 11
7. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013; 54: 1420-1427
8. Harada R, Okamura N, Furumoto S, et al. Comparison of the binding characteristics of [18F]THK-523, and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging 2013; 40: 125-132
9. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381
10. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau, and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373-379
11. Schoonenboom NSM, Pijnenburg YAL, Mulder C, et al. Amyloid beta(1-42), and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62: 1580-1584
12. Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787-800
13. Johnson KA, Schultz A, Betensky RA, et al. Tau PET imaging in aging, and early Alzheimer's disease. Ann Neurol 2016; 79: 110-119
14. Morris JC. The Clinical Dementia Rating (CDR): current version, and scoring rules. Neurology 1993; 43: 2412-2414
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
16. Weschler D. WMS-R: Weschler Memory Scale-Revised Manual. New York: Psychological Corporation/HBJ; 1987
17. Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18)F]T807. J Labelled Comp Radiopharm 2013; 56: 736-740
18. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden, and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234
19. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging, and Alzheimer's disease. Neurology 1999; 52: 1158-1165
20. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress, and future directions. Lancet Neurol 2015; 14: 114-124
21. Mormino EC, Betensky RA, Hedden T, et al. Amyloid, and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014; 82: 1760-1767
22. Toledo JB, Zetterberg H, van Harten AC, et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 2015; 138: 2701-2715
23. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical, and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597-609
24. Dagley A, LaPoint M, Huijbers W, et al. Harvard Aging Brain Study: dataset, and accessibility. Neuroimage Epub 2015 Apr 3